CardioNova initiates Phase 1b clinical trial with AtheroNovas AHRO-001 AtheroNova Inc.

We shall look at markers for inflammatory response, statin interaction and reverse cholesterol transport, amongst others. This study will create a wealth of info in the near term as we anticipate topline data in 6-8 months. The scholarly research will evaluate lipid profiles, define gastrointestinal pharmacokinetics and tolerability of graduated dosing for active transportation stimulation; as well as the hepatic cholesterol synthesis and pharmacokinetics of co-administration of a statin with AHRO-001 in a few of the topics in the study.. CardioNova initiates Phase 1b clinical trial with AtheroNova’s AHRO-001 AtheroNova Inc. , a biotech company centered on the study and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, announces that its partner today, CardioNova, has accomplished 1st dosing of subjects because of its Phase 1b scientific trial with AtheroNova's lead compound, AHRO-001.Recently, nonsteroidal anti-inflammatory drugs have been used to treat some patients with this condition, but these compounds frequently produce significant unwanted effects, including gastrointestinal bleeding and ulcerations, according to Giardiello. Previous observational studies in populations that consume large amounts of curry, along with laboratory analysis on rodents have strongly suggested that curcumin – – a comparatively innocuous yellow pigment extracted from turmeric, the powdered base of the herb curcuma longa and one of many substances in Asian curries – – may be effective in preventing and/or treating cancer in the low intestine, relating to Cruz-Correa.

Other Posts From Category "men's health":

Related Posts